Proactive Investors UK | Fusion IP's Diurnal gets European boost for infant hydrocortisone treatment Proactive Investors UK Diurnal, one of Fusion IP's (LON:FIP) portfolio of university spin-off companies, has cleared a major regulatory hurdel in Europe for Infacort, its hydrocortisone treatment for children. The European Medicines Agency (EMA) has approved a Paediatric ... Fusion IP overcomes European hurdle Diurnal paediatric investigation plan gets EMA approval University spin-out overcomes major hurdle |
